Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma
Open Access
- 31 July 2020
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 81 (11), e215
- https://doi.org/10.1136/annrheumdis-2020-218626
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammationInternational Journal of Infectious Diseases, 2020
- Rational use of tocilizumab in COVID-19Annals Of The Rheumatic Diseases, 2020
- Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control studyAnnals Of The Rheumatic Diseases, 2020
- Tocilizumab in patients with severe COVID-19: a retrospective cohort studyThe Lancet Rheumatology, 2020
- Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort studyEuropean Journal of Internal Medicine, 2020
- Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, ItalyAutoimmunity Reviews, 2020